adrenal insufficiency
Suspected adrenal crisis is a clinical diagnosis: give IV hydrocortisone 100 mg immediately plus isotonic crystalloid — never wait for cortisol or ACTH results. Primary adrenal insufficiency causes hyperpigmentation, salt craving, and hyperkalaemia (aldosterone lost, needs fludrocortisone); central and glucocorticoid-induced adrenal insufficiency spare mineralocorticoids (no hyperkalaemia, no hyperpigmentation, never fludrocortisone). Always replace glucocorticoids before starting levothyroxine in coexisting hypothyroidism.
classification and clinical clues
| feature | primary (adrenal) | central (pituitary/hypothalamic) | glucocorticoid-induced |
|---|---|---|---|
| commonest cause | autoimmune (21-hydroxylase Ab; Addison disease), TB, haemorrhage, metastases, drugs (ketoconazole, etomidate) | pituitary tumour/surgery/radiation, ICI hypophysitis, apoplexy | exogenous systemic, high-dose inhaled, intra-articular, or topical glucocorticoids ≥3–4 wk |
| ACTH | high (>2× ULN) | low or inappropriately normal | low or inappropriately normal |
| aldosterone / renin | low aldosterone, high renin | preserved (RAAS intact) | preserved (RAAS intact) |
| electrolytes | hyponatraemia, hyperkalaemia, non-anion gap acidosis | hyponatraemia (excess AVP), normal K⁺ | hyponatraemia, normal K⁺ |
| hyperpigmentation | yes (high POMC/MSH in creases, scars, buccal mucosa) | no | no |
| mineralocorticoid Rx | yes (fludrocortisone) | no | no |
- Non-specific symptoms common to all types: fatigue, weight loss, anorexia, nausea/vomiting, abdominal pain, postural dizziness, hypoglycaemia
- Autoimmune primary adrenal insufficiency (PAI) clusters with autoimmune thyroid disease, type 1 diabetes, premature ovarian insufficiency, vitiligo, and coeliac disease (APS-2); screen periodically for thyroid dysfunction and diabetes
diagnosis
primary and central adrenal insufficiency (ES 2016)
- Paired 08:00–09:00 serum cortisol and plasma ACTH (draw off exogenous steroids: hold hydrocortisone ≥18–24 h, longer for synthetic steroids)
- Morning cortisol <140 nmol/L (PAI) or <80 nmol/L (central) is strongly suggestive of AI; paired ACTH >2× ULN distinguishes PAI from central AI
- Morning cortisol >400–500 nmol/L (assay-dependent; newer monoclonal/LC-MS/MS assays have lower exclusion cut-offs around 300–350 nmol/L) generally excludes AI
- Avoid testing while on oral oestrogen (raises CBG → falsely normal total cortisol); assess assay-specific cut-offs
- Standard 250 µg IV cosyntropin (ACTH 1–24) stimulation test: gold standard for PAI (moderate accuracy / lower sensitivity in central AI — insulin tolerance or glucagon testing if equivocal)
- Peak cortisol at 30 or 60 min <500 nmol/L (polyclonal assay; lower cut-offs ~350–400 nmol/L on newer monoclonal/LC-MS/MS assays — check local lab reference) confirms AI
- Pitfall in acute central AI: within 4–6 weeks of pituitary surgery, apoplexy, or stalk injury, the adrenal cortex has not yet atrophied, so cosyntropin stimulation can be falsely normal — rely on morning cortisol and clinical context
- Low-dose (1 µg) cosyntropin test is suggested only if cosyntropin is in short supply
- Aetiologic workup once PAI confirmed:
- 21-hydroxylase autoantibodies first; if negative, obtain adrenal CT (haemorrhage, TB calcification, metastases, lymphoma, fungal infection)
- In young males with negative 21-hydroxylase antibodies and no structural cause, measure very-long-chain fatty acids (adrenoleukodystrophy)
- Screen renin and aldosterone (or electrolytes/BP) to confirm mineralocorticoid deficiency
glucocorticoid-induced AI and tapering (ESE/ES 2024)
- Short courses (<3–4 weeks): any dose can be stopped without tapering and without HPA-axis testing
- Longer courses (≥3–4 weeks): taper only once the underlying disease is controlled, down to a physiologic equivalent (e.g., prednisone 4–6 mg/day)
- Switch long-acting steroids (dexamethasone, betamethasone) to shorter-acting hydrocortisone or prednisone once high-potency therapy is no longer needed
- Do not test the HPA axis while the patient is still on supraphysiologic doses
- Assessing HPA-axis recovery once on physiologic dose (hold morning dose 24 h before blood draw):
- Morning serum cortisol is the first-line test (avoid routine dynamic stimulation testing)
- >300 nmol/L: HPA axis recovered → stop glucocorticoids safely
- 150–300 nmol/L: indeterminate → continue physiologic dose and repeat morning cortisol in weeks to months
- <150 nmol/L: suppressed → continue physiologic dose and repeat in several months (recovery often takes 6–12+ months)
- Glucocorticoid withdrawal syndrome (myalgias, fatigue, nausea, mood lability despite adequate cortisol): distinguish from true AI; temporarily step back up to the last tolerated dose and taper more slowly
- Never prescribe fludrocortisone for glucocorticoid-induced AI
adrenal crisis
Refractory hypotension, hyponatraemia, hyperkalaemia, vomiting, or acute decompensation in known/suspected AI — treat before labs return.
- draw cortisol/ACTH if immediate, then give hydrocortisone 100 mg IV bolus (or IM) without waiting for results
- resuscitate with 1 L 0.9% NaCl IV over 1 h, then isotonic crystalloid guided by haemodynamics and electrolytes
- continue hydrocortisone 200 mg/24 h IV infusion (or 50 mg IV/IM q6h); step down to 100 mg/24 h next day if stable
- check glucose (give IV dextrose for hypoglycaemia) and treat the precipitating infection, trauma, or missed doses
- adding fludrocortisone while on hydrocortisone >50 mg/day (high-dose hydrocortisone provides ample mineralocorticoid effect)
chronic replacement and sick-day rules
glucocorticoid replacement
- Hydrocortisone 15–25 mg/day in 2–3 divided doses (highest dose on waking, e.g., 10 mg AM + 5 mg early afternoon, or 10 + 5 + 5 mg; avoid late evening doses to prevent insomnia) — or cortisone acetate 20–35 mg/day in 2–3 doses; prednisone 3–5 mg once daily is an alternative when adherence is difficult
- Monitoring: titrate strictly by clinical response (energy, weight, BP, Cushingoid signs) — do not use serum cortisol or ACTH levels to adjust maintenance doses
- Pregnancy: use hydrocortisone, prednisone, or prednisolone (inactivated by placental 11β-HSD2); avoid dexamethasone (crosses placenta). Dose often increases by 20–40% in the third trimester; give major surgical stress dosing during active labour
mineralocorticoid replacement (PAI only)
- Fludrocortisone 50–100 µg PO once daily (do not restrict dietary sodium)
- Monitor clinically (postural hypotension, salt craving, peripheral oedema, BP) and with electrolytes (Na⁺, K⁺) ± plasma renin
- If hypertension develops: reduce fludrocortisone dose first; if BP remains high, add an antihypertensive and continue fludrocortisone (never stop fludrocortisone completely in confirmed PAI)
sick-day rules and crisis prevention (ES 2016)
- Every patient needs a steroid emergency card / medical alert bracelet, written sick-day instructions, and an emergency injectable hydrocortisone 100 mg IM kit
- Sick-day rule 1 (minor–moderate illness): febrile illness, illness requiring bed rest, infection needing antibiotics, or minor outpatient/dental procedure → double (or triple if fever >39 °C) the routine oral glucocorticoid dose until recovered
- Sick-day rule 2 (severe illness, persistent vomiting/diarrhoea, fasting for colonoscopy, trauma, surgery): switch to parenteral hydrocortisone (100 mg IV/IM bolus, then 200 mg/24 h continuous infusion or 50 mg IV/IM q6h)
In coexisting hypothyroidism and suspected adrenal insufficiency (especially hypopituitarism or APS-2), always start glucocorticoids before levothyroxine. Thyroxine accelerates cortisol clearance via 11β-HSD2 and can precipitate fatal adrenal crisis.
Prepared 2026-11-19. Not yet verified — check every number against the sources.